top of page
View Mind.png
One-of-a-kind Solution
for Precision Measurement of Neurocognitive Health

 

ViewMind is a digital health and artificial intelligence company that provides clinically validated solutions for precision assessment of neurocognitive disorders.

 

ViewMind’s technology is based on ocular digital phenotyping that measures the state of 16 cognitive domains and 19 brain related brain regions. It delivers groundbreaking levels of accuracy and correlates with biomarkers, neuroimaging and EEG.

ViewMind
Screenshot 2024-01-06 at 10-57-56 adad.webp (PNG Image 2776 × 1488 pixels) — Scaled (47%).png

About ViewMind

Based on 20 Years of Scientific Research

 

ViewMind’s fundamental technology is based on research and development led by Dr. Gerardo Fernandez, ViewMind’s Chief Science Officer and Co-founder. ViewMind developed a technology that phenotypes eye movement responses to visual stimuli and the functioning of specific cognitive domains and related areas of the brain.

 

ViewMind is collaborating with various academic institutions, hospitals, research facilities, key opinion leaders, and pharmaceutical companies to test and iterate on this breakthrough technology.

 

We are interested in additional partnerships for:

 

  • Commercial Phase I, II & III, IV pharmaceutical clinical studies for therapeutics that alter cognitive function.

  • Commercialization partners.

  • New studies with clinical centers, and patient advocacy groups.

ViewMind
ViewMind Awards

ViewMind Difference

Precision Advantage

ViewMind’s patented technology is based on fundamental scientific research performed over 20 years under the leadership

of ViewMind’s Chief Science Officer, Gerardo Fernandez PhD

Dr. Fernandez conducted research at some of the world’s leading institutions, including in Argentina, the United Kingdom, the United States, and Germany.

 

ViewMind technology shows remarkable accuracy, as evidenced in 25 peer-reviewed publications and supported by clinical data on thousands of patients studied across four continents in scores of clinical trials, including a 4-year longitudinal study and studies in familial populations.

Published Studies:

  • Alzheimer’s Disease (AD) and Mild Cognitive Impairment (MCI)

  • Multiple sclerosis (MS)

Clinical Studies
Conducted or in progress:

  • MCI & Alzheimer’s disease

  • Multiple sclerosis

  • Neurological Long COVID

  • Parkinson’s disease

View Mind

How It Works

ViewMind Gathers and Analyzes Eye Movement Patterns to Produce Accurate, AI-Powered Results

 

Traditional neuropsychological assessment tests are primarily concerned with behavioral response. Is the provided answer correct or incorrect? The majority of the cognitive decision-making signal is disregarded.

 

ViewMind’s technology analyzes every cognitive processing step based on eye-movement responses to visual stimuli. The signal fidelity is over a million times greater than traditional assessments. ViewMind employs Ocular Digital Phenotyping using context-aware

artificial intelligence to assess the status of 16 cognitive domains and 19 related brain regions. In the second analysis stage, the phenotypes of neurodegenerative diseases have been derived and validated in collaboration with some of the world’s leading expert clinicians and researchers.

 

ViewMind measures eye-movement responses to visual stimuli using VR headsets that are more accurate compared to separate camera sensors. They also provide a clinically controlled environment. Eye movement patterns change precisely and repeatedly based

on alterations in cognition, like fingerprints, so having the most sensitive instrument for these measurements is key.

VM 1.png

Virtual Reality Headset

VR headset enables ViewMind to conduct an analysis of eye movement in a controlled environment, using high-fidelity equipment for the most accurate results.

VM 2.png

Eye Movement Assessment

ViewMind tracks reproducible

phenotypic eye movement

patterns to reveal the state of

cognitive domains and related

brain regions.

VM 3.png

AI-Based Analysis

ViewMind’s patented software identifies minor deviations in oculomotor patterns, quantifies them, and correlates them with the eye patterns of specific pathologies and neurocognitive functions.

DNA ViewMind

ViewMind for Private and Public Healthcare Institutions

Precision Care for
Neurological Diseases

 

ViewMind has the potential to significantly impact healthcare for brain diseases by addressing these unmet needs:
 

  • Challenging, costly, time-consuming neurological assessments.

  • High misdiagnosis rates: 18% for Alzheimer’s, 30% for Parkinson’s, and 20% for multiple sclerosis.

  • Lack of objective data to measure a patient’s response to treatment.

Screenshot_2024-01-08_at_15-37-42_Group-
How Healthcare Institutions can Use ViewMind
in Their Care Settings?
VM.webp

Brain Health Assessment

Quantify Neurocognitive and Brain Alterations

  • Measure the health of 16 cognitive domains and 19 related brain regions in a 15-minute non-invasive test.

 

  • Specific test batteries can be used to find ocular patterns characteristic of various neurodegenerative diseases, disease progression, and even subclinical alterations.

VM A.webp

Therapeutic Impact Measurement

Provide Objective Evidence on Drug Impact

  • Select the drug most likely to ameliorate symptoms based on the patient’s ocular digital phenotype.

  • Measure the state of different cognitive domains and related brain regions to track the impact of a therapeutic.

VM B.webp

Neurocognitive Performance Monitoring

Track Neurocognitive Resources and Brain Changes
  • Quantify various aspects of neurocognitive performance and brain function.

 

  • Monitor small changes in neurocognitive performance over time, differentiating between disease-related and age-related alterations.

ViewMind.webp

ViewMind Technology

Non-Invasive Solution for Hospitals, Neurology Centers,
Memory Clinics, and Elderly Care Centers
VM 1st.png

Patient Assesment

A clinical research coordinator or

nurse practitioner can complete an

online ViewMind training and

certification in under 60 minutes.

VM 2nd.png

Analysis of Oculomotor Patterns

After collecting data from more

than a billion variable permutations, ViewMind’s proprietary context-aware AI

algorithms analyze the data and

identify ocular digital phenotype

patterns associated with

specific neurocognitive disorders.

VM 3rd.png

Report

ViewMind generates a

presumptive diagnostic report

detailing information about the

patient’s cognitive state based on

the analysis. This report is made

available to the physician.

How healthcare professionals identify patients’ conditions with ViewMind

Traditional Neurocognitive Assessments can be
Inconclusive and Non-Specific. ViewMind Offers Insights
into Patients’ Cognitive Health.

Distinguishing between Different Neurocognitive Diseases

 

A 45-year-old patient visited a neurologist showing attention problems, continuous headaches, and fatigue.

He had suffered from similar problems all his life, but nobody could diagnose his condition. The patient underwent ViewMind’s evaluations and our algorithms identified eye movement patterns consistent with dyslexia.

The patient was diagnosed and started treatment for dyslexia, which resulted in a tangible improvement in his quality of life.

“The neurocognitive assessment solutions offered by ViewMind reveal insight into a patient’s cognitive process and are extremely useful to aid in the assessment process to improve patient outcomes”.

 

Dr Gustavo Echevarria
Doctor

Providing a Differential Assessment based on Eye Movement Patterns

 

A 65-year-old patient was showing an increasing level of cognitive impairment.

A number of traditional neurocognitive assessments were performed and the results were inconclusive. The possible causes were Parkinson’s disease, Alzheimer’s disease, or MCI caused by depression (requiring 3 very different treatments).

The patient underwent ViewMind’s evaluations, and our algorithms were able to identify that when the patient was presented with very specific visual exercises, the ocular movement patterns were not characteristic of Alzheimer’s or Parkinson’s.

“ViewMind’s precision neurocogntive digital biomarkers to assist a doctor make a differential diagnosis are unique and highly valuable in the clinical setting”.

Dr Gustavo Sgrilli
Doctor

bottom of page